Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 08 Oct 2016
At a glance
- Drugs CEP 37250 (Primary)
- Indications Adenocarcinoma; Colon cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Kyowa Hakko Kirin
- 08 Oct 2016 Status changed from completed to discontinued according to results published in the Targeted Oncology.
- 17 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jan 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Feb 2015, as reported by ClinicalTrials.gov.